Navigation Links
NeurogesX to Present at Susquehanna Financial Group's 2nd Annual SIGnificant Options in Healthcare Conference
Date:2/28/2008

SAN MATEO, Calif., Feb. 28 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, Chief Executive Officer, is scheduled to present to a panel focused on pain management at Susquehanna Financial Group's 2nd Annual SIGnificant Investment Options in Healthcare Conference. Mr. DiTonno is scheduled to present on Tuesday, March 4, 2008 in New York City.

Event: SIGnificant Investment Options in Healthcare Conference

Date: Tuesday, March 4, 2008

Time: 4:00 p.m. Eastern Time

Place: The W Hotel

541 Lexington Avenue at 49th Street

New York City, NY

An audio Web cast of the Company's presentations will be available by accessing the investor relations section of NeurogesX' Web site at http://www.neurogesx.com. A replay of the presentation will be available for 15 days.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements concerning future presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX The Ruth Group

Anthony DiTonno Investors / Media

(650) 358-3330 Stephanie Carrington / Jason Rando

aditonno@neurogesx.com (646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NeurogesX to Present at RBC Capital Markets 2007 Healthcare Conference
2. NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007
3. Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the Investment in Innovation (In3) West Conference on February 29, 2008 in Las Vegas, NV
4. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
5. Representative Greg Harris, Senator Jacqueline Collins, Senator Iris Martinez and Fellow State Legislators to Join Susan G. Komen for the Cure in Announcing Groundbreaking Legislation to Reduce Breast Cancer Disparities; Will Hold Press Conference Friday
6. Nationwide to Present at Citigroup Global Property CEO Conference
7. Urine protein may be present before hypertension diagnosis in at-risk adolescents
8. Abaxis, Inc. to Present at the Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
9. Ventas to Present at the Citi 2008 Global Property CEO Conference
10. Aflac Incorporated to Present at the Raymond James 29th Annual Institutional Investors Conference
11. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... , ... February 13, 2016 , ... Hidden Cypress in Sun City is the place ... facial plastic surgery. Dr. Frederick Weniger will be hosting this educational seminar from ... event, and there will be special pricing on offers. In addition, prizes will be given ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... The producers ... impact of American businesses. , The increasingly modern world of instantaneous consumption proves ... on non-renewable energy sources such as oil and coal, which pollutes our air, water, ...
(Date:2/13/2016)... ... 13, 2016 , ... DDi , a Makro company, ... for its expertise in eClinical Solutions. DDi has built its solution competency with ... of global clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Coco Libre, the ... in Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians ... stay hydrated before the big event. The invitation-only gifting suite, held this year at ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... and Company (NYSE: LLY ) today announced that the ... patent would not presently be infringed by Actavis marketing pemetrexed ... Italy and Spain ... --> --> In ... Lilly,s patent would be indirectly infringed by Actavis marketing certain ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary goal ... future adoption patterns on the usage of liquid biopsy. ... following: - Timeframe of liquid biopsy adoption ... cfDNA and Evs—by organization type - Sample inflow to ... blood, saliva, stool, serum, and so on. - Correlation ...
Breaking Medicine Technology: